InvestorsHub Logo
Followers 2
Posts 514
Boards Moderated 0
Alias Born 06/15/2007

Re: None

Friday, 11/07/2014 1:53:55 AM

Friday, November 07, 2014 1:53:55 AM

Post# of 15819
Rolapitant NDA accepted

On November 4, 2014 the Company’s new drug application for oral rolapitant was accepted for review by the U.S. Food and Drug Administration. As a result, the Company is obligated to make a $5.0 million milestone payment in November 2014 to OPKO Health, or OPKO, consistent with the terms of the Company’s license agreement with OPKO.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent OPK News